Brief: Nanobiotix Announces New Data Showing Disease Control And Tumor Response In Patients Treated With Rt-Activated Nbtxr3 Followed By Anti-Pd-1 For 2L+ R/M Hnscc Naïve Or Resistant To Prior Anti-Pd-1 Therapy
02/06/2024 15:03
June 2 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES NEW DATA SHOWING DISEASE CONTROL AND
TUMOR
RESPONSE IN PATIENTS TREATED WITH RT-ACTIVATED NBTXR3 FOLLOWED
BY ANTI-PD-1 FOR 2L+ R/M HNSCC NAÏVE OR RESISTANT TO PRIOR
ANTI-PD-1 THERAPY
* NANOBIOTIX SA- EXPECTS TO PROVIDE FIRST DATA FROM COHORT 3
OF
STUDY 1100 DOSE EXPANSION PART IN 2025
Source text for Eikon: ID:nGNXbZB0wQ
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering